Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-07-18

FDA Approved: AMBRISENTAN — Supplemental Application (Aurobindo Pharma Limited)

View source ↗

Summary

FDA approved a supplemental application for Ambrisentan by Aurobindo Pharma Limited, authorizing a generic version of the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Ambrisentan (Ambrisentan)

Snippet

SUPPL AP for AMBRISENTAN (AMBRISENTAN)